Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Rationale: In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) significantly reduced all-cause mortality compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, Fernando J., Rabe, Klaus F., Ferguson, Gary T., Wedzicha, Jadwiga A., Singh, Dave, Wang, Chen, Rossman, Kimberly, St. Rose, Earl, Trivedi, Roopa, Ballal, Shaila, Darken, Patrick, Aurivillius, Magnus, Reisner, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924571/
https://www.ncbi.nlm.nih.gov/pubmed/33252985
http://dx.doi.org/10.1164/rccm.202006-2618OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924571/
https://www.ncbi.nlm.nih.gov/pubmed/33252985
http://dx.doi.org/10.1164/rccm.202006-2618OC

Ejemplares similares